Sunitinib effective for rare thymus cancer.
In a phase II trial, the tyrosine kinase inhibitor sunitinib was effective in previously treated patients with thymic carcinoma, offering the first viable second-line treatment option for patients with this rare and aggressive form of thymus cancer.